Category - Developments

Developments

FDA clears Ziopharm Oncology IND for CAR-T therapy

The FDA has cleared Ziopharm Oncology’s (NASDAQ:ZIOP) IND for CD19-specific CAR-T for the treatment of relapsed CD19+ leukemias and lymphomas. The drug candidate is based on Ziopharm’s non-viral T cell modification...

October 1, 2019

Developments

Catabasis Pharma exceeds target enrollment for global Phase 3 DMD trial

Catabasis Pharmaceuticals (NASDAQ:CATB) completed enrollment for its Phase 3 trial of edasalonexent for the treatment Duchenne muscular dystrophy (DMD). Taking place at 40 clinical sites in eight countries, the trial...

October 1, 2019

Developments

Heron resubmits NDA for postoperative pain drug

Heron Therapeutics (NASDAQ:HRTX) resubmitted its NDA for HTX-011 – a dual-acting combination of the local anesthetic bupivacaine and the nonsteroidal anti-inflammatory drug, meloxicam – to the FDA. The resubmission was...

October 1, 2019

Developments

BeyondSpring presents novel NSCLC study design for plinabulin

At the recent European Society for Medical Oncology Congress, BeyondSpring Pharmaceuticals (NASDAQ:BYSI) presented its novel study design for DUBLIN-3, a global Phase 3 trial assessing plinabulin in non-small cell lung...

October 1, 2019

Developments

Titan Pharma’s Probuphine now available at Crossroads of Southern Nevada rehabilitation facilities

Titan Pharmaceuticals (NASDAQ:TTNP) reported that Crossroads of Southern Nevada rehabilitation facility has trained health care providers in the insertion and removal of Probuphine implants, which will now be offered to...

October 1, 2019

Developments

Geron imetelstat gets FDA fast track designation for myelofibrosis

Geron’s (NASDAQ:GERN) imetelstat, a telomerase inhibitor, received FDA fast track designation for the treatment of relapsed/refractory myelofibrosis (MF). MF is a chronic blood cancer that impairs normal blood...

September 30, 2019

Developments

AVEO Oncology begins enrollment for Phase 1b/2 study of FOTIVDA for HCC

AVEO Oncology (NASDAQ:AVEO) began enrolling patients for its Phase 1b/2 clinical trial evaluating FOTIVDA, in combination with AstraZeneca’s IMFINZI, in patients with hepatocellular carcinoma (HCC) who have not received...

September 30, 2019

Developments

FDA clears Turning Point Therapeutics’ IND for TPX-0046

The FDA cleared Turning Point Therapeutics’ (NASDAQ:TPTX) IND for TPX-0046, a dual RET and SRC tyrosine kinase inhibitor (TKI) being developed for the treatment of solid tumors. The company plans to initiate a first-in...

September 30, 2019

Developments

Zenabis to supply cannabis extracts for PAX Labs’ Era vaporizer pods

Zenabis Global (TSX:ZENA) has agreed to supply cannabis extracts for PAX Era pods, which are designed for use with PAX Labs’ Era vaporizer device. Under the accord, Zenabis will supply cannabis extracts in the form...

September 30, 2019

Developments

Cheryl Reicin, renowned Canadian corporate lawyer, recognized at LMG Life Sciences awards

Cheryl Reicin, partner at Torys, was named Canada’s financial and corporate attorney of the year at the seventh annual LMG Life Sciences awards. Ms. Reicin is the practice leader of Torys’ life science group...

September 27, 2019

Category - Developments

FDA clears Ziopharm Oncology IND for CAR-T therapy

Catabasis Pharma exceeds target enrollment for global Phase 3 DMD trial

Heron resubmits NDA for postoperative pain drug

BeyondSpring presents novel NSCLC study design for plinabulin

Titan Pharma’s Probuphine now available at Crossroads of Southern Nevada rehabilitation facilities

Geron imetelstat gets FDA fast track designation for myelofibrosis

AVEO Oncology begins enrollment for Phase 1b/2 study of FOTIVDA for HCC

FDA clears Turning Point Therapeutics’ IND for TPX-0046

Zenabis to supply cannabis extracts for PAX Labs’ Era vaporizer pods

Cheryl Reicin, renowned Canadian corporate lawyer, recognized at LMG Life Sciences awards

General

More